Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
Citius Pharmaceuticals Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at two September conferences in New York City: the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference (September 9) and the H.C. Wainwright 28th Annual Global Investment Conference (September 15). Presentations will cover the ongoing commercialization of LYMPHIR (denileukin diftitox-cxdl) by majority-owned subsidiary Citius Oncology (Nasdaq: CTOR), plus the late-stage pipeline including Mino-Lok and Halo-Lido.
Key figures
- Lympir launch date
- December 2025
- Lympir initial market estimate
- $400 million
- Parent ownership of citius oncology
- approximately 62%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.